Dr. Reddy's Laboratories Ltd (RDY)
RDY trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), period ending 2025-03-31, https://www.sec.gov/Archives/edgar/data/1135951/000157587225000393/0001575872-25-000393-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), period ending 2025-03-31. Converted from INR at 95.1570 per USD (ECB reference rate).
Profile
| Field | Value |
|---|---|
| Ticker | RDY on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | India |
| IPO year | Not reported by the screener |
| SEC CIK | 0001135951 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | K7 |
Financials · 2024
| Line | Value |
|---|---|
| Revenue | $3.4B |
| Net income | $594.2M |
| Operating income | Not in SEC XBRL data |
| Net margin | 17.4% |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | Not in SEC XBRL data |
| Total assets | Not in SEC XBRL data |
| P/E (computed) | 17.9× |
| P/S (computed) | 3.1× |
Reported in INR; shown in US dollars.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest annual report FORM 20-F | 20-F | 2026-05-29 |
| Latest quarterly / interim FORM 6-K | 6-K | 2026-10-14 |
Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +4.4% |
| 1 month | +10.9% |
| 3 months | +0.8% |
| Year to date | -8.8% |
| 1 year | -10.8% |
| From 52-week high | -16.7% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| BMRN | BioMarin Pharmaceutical Inc. | $54.38 | -1.82% | $10.5B |
| MDGL | Madrigal Pharmaceuticals Inc. | $452.12 | -3.22% | $10.4B |
| ELAN | Elanco Animal Health Incorporated | $22.41 | -0.67% | $11.2B |
| BBIO | BridgeBio Pharma Inc. | $63.30 | -3.73% | $12.4B |
| SMMT | Summit Therapeutics Inc. Common Stock | $15.52 | -9.40% | $12.4B |
| PTGX | Protagonist Therapeutics Inc. | $138.49 | -4.41% | $9.0B |
| CORT | Corcept Therapeutics Incorporated | $117.80 | -2.80% | $12.7B |
| CYTK | Cytokinetics Incorporated | $61.62 | -1.86% | $8.6B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier